Recent advances in viral hepatitis

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 9, Issue 6, 2009, Pages 613-616

  Foster, Graham R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Disease progression; Hepatitis B; Hepatitis C; Natural history

Indexed keywords

ENTECAVIR; LAMIVUDINE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; TENOFOVIR; VIRUS DNA;

CLINICAL TRIAL; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMIGRATION; INCIDENCE; LIVER FUNCTION TEST; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REVIEW; SEROPREVALENCE; UNITED KINGDOM; VIREMIA; VIRUS CARRIER; VIRUS HEPATITIS; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 71849099293     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.9-6-613     Document Type: Review

References (18)

1. Health Protection Agency. Hepatitis C in England: The Health Protection Agency annual report 2007. London: HPA, 2007.
2. Hepatitis B Foundation. Hepatitis B: out of the shadows. London: Hepatitis B Foundation, 2007.
3. World Health Organization. Global surveillance and control of hepatitis C. J Viral Hep 1999;6:35-47.
4. Mann AG, Trotter CL, Adekoyejo Balogun M, Ramsay ME. Hepatitis C in ethnic minority populations in England. J Viral Hepat 2008;15:421-426 (Pubitemid 351677547)
5. Uddin G, Shoeb D, Solaiman S et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence can not necessarily be predicted from the prevalence in the country of origin. J Viral Hepatitis 2009; in press.
6. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-431
7. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472 (Pubitemid 27078833)
8. Ferenci P, Ferenci S, Datz C et al. Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. J Hepatol 2007;47:31-36 (Pubitemid 46817684)
9. D'Souza R, Glynn MJ, Ushiro-Lumb I et al. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol 2005;3:910-917 (Pubitemid 41219295)
10. D'Souza R, Foster GR. Diagnosis and treatment of chronic hepatitis. B J R Soc Med 2004;97:318-321
11. Kumar M, Sarin SK, Hissar S et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134:1376-1384 (Pubitemid 351615375)
12. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686 (Pubitemid 43374518)
13. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539
14. D'Souza R, Foster GR. Diagnosis and treatment of hepatitis C. J R Soc Med 2004;97:223-225
15. National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. London: NICE, 2006.
16. Wilkinson M, Crawford V, Tippet A et al. Community based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite on-going drug use (HCV in drug users). Aliment Pharmacol Ther 2009;29:29-37.
17. Ferenci P. Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future. Minerva Gastroenterol Dietol 2006;52:157-174 (Pubitemid 43774325)
18. Kieffer TL, Sarrazin C, Miller JS et al. Telaprevir and pegylated interferon-alpha- 2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-639 (Pubitemid 47436107)